We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance
Read MoreHide Full Article
Merck (MRK - Free Report) announced that the FDA has accepted the biologics license application (BLA) for its investigational prophylactic long-acting monoclonal antibody, clesrovimab (MK-1654), designed to protect infants from respiratory syncytial virus (RSV) disease entering their first RSV season.
With the FDA accepting the BLA for review, a decision from the regulatory body is expected on June 10, 2025.
Clesrovimab is likely to be available by July 2025 in the United States.
If approved, clesrovimab can help address the burden of RSV disease in time for the 2025-26 RSV season.
Year to date, shares of Merck have declined 8.3% against the industry’s rise of 5.3%.
Image Source: Zacks Investment Research
More on MRK's BLA for Clesrovimab
The above BLA for clesrovimab was based on data from the pivotal phase IIb/III CLEVER (MK-1654-004) study and interim data from the ongoing phase III SMART (MK-1654-007) study.
The placebo-controlled CLEVER study evaluated a single dose of clesrovimab administered to healthy preterm and full-term infants (birth to one year of age), while the SMART study investigated the safety and efficacy of clesrovimab versus Synagis (palivizumab) in infants and children who are at increased risk for severe RSV disease.
Data from the CLEVER study showed that treatment with a single dose of clesrovimab significantly reduced the incidence of RSV disease and hospitalization in healthy preterm and full-term infants.
Other RSV Antibodies/Vaccines Available in the Market
AstraZeneca (AZN - Free Report) and Sanofi’s (SNY - Free Report) RSV antibody Beyfortus (nirsevimab) was approved in the United States in July 2023 for newborns and infants.
AstraZeneca records a 50% share of gross profits on sales of Beyfortus in major markets outside the United States, which it receives from Sanofi.
AZN also records Beyfortus product sales from products supplied to partner SNY.
In the first nine months of 2024, Beyfortus recorded sales worth €845 million. Beyfortus sales benefited from early deliveries in the United States and launch in countries like Canada, France, Germany, Spain, Portugal, Belgium and Ireland.
Pfizer’s (PFE - Free Report) RSV vaccine, Abrysvo, was launched to help protect older adults as well as infants through maternal immunization in the United States as well as in the EU in 2023.
PFE’s Abrysvo recorded sales of $557 million in the first nine months of 2024.
PFE’s Abrysvo was approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 18-59 years who are at increased risk of the disease by the FDA in October 2024.
GSK’s Arexvy is currently approved in the United States, Europe, Japan and several other countries for adults aged 60 and above for the prevention of LRTD caused by RSV. This was the first RSV vaccine for older adults to be approved anywhere in the world.
In the first nine months of 2024, Arexvy generated £432 million in sales.
Arexvy was approved for high-risk adults aged 50-59 years in the United States and the European Union in June and August 2024, respectively.
Image: Shutterstock
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance
Merck (MRK - Free Report) announced that the FDA has accepted the biologics license application (BLA) for its investigational prophylactic long-acting monoclonal antibody, clesrovimab (MK-1654), designed to protect infants from respiratory syncytial virus (RSV) disease entering their first RSV season.
With the FDA accepting the BLA for review, a decision from the regulatory body is expected on June 10, 2025.
Clesrovimab is likely to be available by July 2025 in the United States.
If approved, clesrovimab can help address the burden of RSV disease in time for the 2025-26 RSV season.
Year to date, shares of Merck have declined 8.3% against the industry’s rise of 5.3%.
Image Source: Zacks Investment Research
More on MRK's BLA for Clesrovimab
The above BLA for clesrovimab was based on data from the pivotal phase IIb/III CLEVER (MK-1654-004) study and interim data from the ongoing phase III SMART (MK-1654-007) study.
The placebo-controlled CLEVER study evaluated a single dose of clesrovimab administered to healthy preterm and full-term infants (birth to one year of age), while the SMART study investigated the safety and efficacy of clesrovimab versus Synagis (palivizumab) in infants and children who are at increased risk for severe RSV disease.
Data from the CLEVER study showed that treatment with a single dose of clesrovimab significantly reduced the incidence of RSV disease and hospitalization in healthy preterm and full-term infants.
Other RSV Antibodies/Vaccines Available in the Market
AstraZeneca (AZN - Free Report) and Sanofi’s (SNY - Free Report) RSV antibody Beyfortus (nirsevimab) was approved in the United States in July 2023 for newborns and infants.
AstraZeneca records a 50% share of gross profits on sales of Beyfortus in major markets outside the United States, which it receives from Sanofi.
AZN also records Beyfortus product sales from products supplied to partner SNY.
In the first nine months of 2024, Beyfortus recorded sales worth €845 million. Beyfortus sales benefited from early deliveries in the United States and launch in countries like Canada, France, Germany, Spain, Portugal, Belgium and Ireland.
Pfizer’s (PFE - Free Report) RSV vaccine, Abrysvo, was launched to help protect older adults as well as infants through maternal immunization in the United States as well as in the EU in 2023.
PFE’s Abrysvo recorded sales of $557 million in the first nine months of 2024.
PFE’s Abrysvo was approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 18-59 years who are at increased risk of the disease by the FDA in October 2024.
GSK’s Arexvy is currently approved in the United States, Europe, Japan and several other countries for adults aged 60 and above for the prevention of LRTD caused by RSV. This was the first RSV vaccine for older adults to be approved anywhere in the world.
In the first nine months of 2024, Arexvy generated £432 million in sales.
Arexvy was approved for high-risk adults aged 50-59 years in the United States and the European Union in June and August 2024, respectively.
MRK's Zacks Rank
Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.